Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04270747 · ClinicalTrials.gov registry record · Phase 3
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 576
- Enrollment target
NCT04270747 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 576 participants.
The verdict
NCT04270747, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 576 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration. Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group A) or aflibercept (Treatment Group B) administered by intravitreal (IVT) injection.
Interventions
- DRUG Aflibercept
- DRUG ABP 938
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 576 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2023-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04270747
The ClinicalTrials.gov registry entry for NCT04270747 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 576 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aflibercept is the first listed.
NCT04270747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04270747 about?
NCT04270747 is a clinical study titled "A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]". The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration. Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group A) or aflibercept (T...
What is the current status of trial NCT04270747?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 576 participants. The study started on 2020-06-22. Estimated completion is 2023-01-30.
What interventions are being tested in trial NCT04270747?
The interventions under investigation include: Aflibercept (DRUG), ABP 938 (DRUG).
Who is sponsoring clinical trial NCT04270747?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.